|
"I think that providers are going to be pretty impressed with the data," said Dr. Beth Jordan, medical director of the Association of Reproductive Health Professionals, which plans to highlight the findings to doctors, nurse practitioners and pharmacists at its annual meeting in September.
Given that 87 percent of U.S. counties have no abortion provider, Jordan said the findings might encourage some primary care doctors to offer abortion using the pills.
"But I don't think it's going to open the floodgates," she said.
In October, the National Abortion Federation, representing 400 centers that provide more than half of abortions in the U.S. and Canada, will review the findings and decide whether to make changes accordingly. Federation President Vicki Saporta said current guidelines allow putting misoprostol in the cheek to dissolve, swallowing it, or inserting it in the vagina, which more than a third of her member clinics do.
Saporta said abortion opponents "have been misleading people into thinking that medical abortion is unsafe," but the study proves the procedure is safe. The cost is $400, only slightly less than the median cost for an early term surgical abortion.
Since approval in 2000, there have been six deaths from sepsis, a bloodstream infection, among the more than 1.1 million American women who have used Mifeprex, most recently one in July 2007. That's a death rate of less than 1 in 167,000, according to the maker, and less than 0.1 percent of patients have needed transfusions.
Misoprostol, which is officially approved in the U.S. for preventing stomach ulcers, is sold under the brand name Cytotec and made by Pfizer Inc.
Winikoff and Saporta both raised concerns about giving a full course of antibiotic treatment to all women to prevent very few infections -- unlike the brief preventive dose given with surgical abortions. They said that could trigger a rare allergic reaction, add to the problem of antibiotic resistance and add to the cost of the procedure -- making it unaffordable in developing countries.
Chris Gacek, a senior fellow at the anti-abortion Family Research Council, said he wasn't surprised by the increasing use of Mifeprex.
"I don't think at this point we're going to do anything" to try to limit its use, he said. "It's hard to know whether this increases the (total) number of abortions."
___
On the Net:
New England Journal of Medicine:
http://www.nejm.org/
Mifeprex site: http://www.earlyoptionpill.com/
[Associated
Press;
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor